AKTS (Aktis Oncology, Inc.) — Stock Analysis, Catalysts & AI Research

Aktis Oncology, Inc.

$24.40

The Read: Aktis Oncology’s stock historically fell on earnings that met estimates but disappointed on guidance or lacked positive pipeline news, yet surged about 20% after strong AACR data and strategic board appointments validated its radiopharmaceutical progress.

Price

Overlays

Panel

AKTS

Hover to view data

No Data

The Stats

Market Cap

N/A

Total outstanding shares value

Earnings Per Share (EPS)

N/A

Latest reported

Net Profit Margin

N/A

Net Income / Revenue

Revenue Growth (YoY)

N/A

Prior year same period

Debt / Equity

N/A

Leverage risk indicator

Dividend Yield

0.00%

Annualized Return

Free Cash Flow

N/A

No data

Aktis Oncology, Inc.

$24.40

Health CareBiotechnology

Price

Overlays

Panel

AKTS

Hover to view data

No Data

The Stats

Market Cap

N/A

Total outstanding shares value

Earnings Per Share (EPS)

N/A

Latest reported

Net Profit Margin

N/A

Net Income / Revenue

Revenue Growth (YoY)

N/A

Prior year same period

Debt / Equity

N/A

Leverage risk indicator

Dividend Yield

0.00%

Annualized Return

Free Cash Flow

N/A

No data

Create your free account to unlock active Expected Moves for AKTS

Expected Moves

Aktis Oncology, Inc.

The Stats

Market Cap

Earnings Per Share (EPS)

Net Profit Margin

Revenue Growth (YoY)

Debt / Equity

Dividend Yield

Free Cash Flow

Create your free account to unlock active Expected Moves for AKTS

Expected Moves

Aktis Oncology, Inc.

The Stats

Market Cap

Earnings Per Share (EPS)

Net Profit Margin

Revenue Growth (YoY)

Debt / Equity

Dividend Yield

Free Cash Flow